Handelsavisen
prelaunch
Companies 000534.SZ
00
000534.SZ Shenzhen Stock Exchange Unclassified

Wedge Industrial Co Ltd

¥36,00
Open in Charts → Attach watcher ⌖
CNY
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
18,3B CNY
P/E
75,6x
EV / Rev
13,0x
Div yield
0,00 %
Op margin
20,8 %
ROE
12,4 %
Net margin
17,8 %
Debt / equity
1,18
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

Wedge Industrial Co Ltd operates in the health care sector, specifically within biotechnology, though its precise business activity remains unclassified in the available data.

Business. Wedge Industrial Co Ltd operates in the health care sector, specifically within biotechnology, though its precise business activity remains unclassified in the available data.

Classification20 %
SectorUnclassified
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
75,6x
P/E
Analysts
not yet wired
Ownership
not yet wired
Profitability
12,4 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 000534.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 000534.SZ. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Wedge Industrial Co Ltd operates in the health care sector, specifically within biotechnology, though its precise business activity remains unclassified in the available data.

    Classification20 %
    SectorUnclassified
    AI synthesis
    GENERATED

    Wedge Industrial Co Ltd maintains a capital structure characterized by significant leverage, with a debt-to-equity ratio of 1.18 and long-term debt totaling 1.90 billion CNY against total equity of 1.60 billion CNY. The company’s liquidity position is tight, evidenced by a current ratio of 1.06, which suggests limited short-term buffer against obligations. Despite generating 113.3 million CNY in operating cash flow, the company reports negative free cash flow of -270.0 million CNY, driven by substantial capital expenditures of 430.4 million CNY. This heavy investment phase results in a net cash deficit when total debt is considered, aligning with the medium liquidity risk assessment.

    Profitability metrics indicate modest returns on capital, with a return on equity (ROE) of 12.45% and a return on assets (ROA) of 4.35%. The company generates a gross profit of 913.9 million CNY on revenue of 1.29 billion CNY, implying a gross margin of approximately 70.8%. However, operating income stands at 199.1 million CNY, resulting in a net income of 197.0 million CNY. Without cohort median data for direct comparison, these returns must be viewed in the context of the high valuation multiples, suggesting that the market prices in significant future growth expectations rather than current profitability efficiency.

    Key takeaways
    • High valuation multiples (P/E 74.65, EV/EBITDA 71.88) reflect significant growth expectations despite modest current returns (ROE 12.45%).
    • Negative free cash flow (-270.0 million CNY) driven by heavy capital expenditures (430.4 million CNY) indicates an aggressive investment phase.
    • Leverage is elevated with a debt-to-equity ratio of 1.18 and long-term debt of 1.90 billion CNY, contributing to medium liquidity risk.
    • Tight liquidity position with a current ratio of 1.06 and negative net cash after debt subtraction.
    • Low dilution risk with no difference between basic and diluted shares outstanding.
    • Lack of segment and geographic data limits detailed operational analysis.

    Bull / Bear case

    Generated · model-assisted
    BULL CASE · 3

    Revenue grew 18.4% annually over four years, demonstrating strong top-line expansion momentum for the company.

    Net income compounded at 19.9% annually, indicating robust profitability growth alongside revenue expansion.

    Net margin of 17.8% ranks above the 75th percentile of peers, reflecting strong cost control.

    BEAR CASE · 4

    Long-term debt surged to 1.7 billion CNY, creating a high credit risk profile for the firm.

    Debt-to-equity ratio of 1.18 is in the bottom quartile, signaling excessive leverage compared to peers.

    Free cash flow deteriorated to negative 431 million CNY, indicating severe cash generation challenges.

    Cash conversion of 0.57 is below the 1.2 cohort median, revealing poor earnings quality.

    In focus — financials by report

    Annual
    ANNUALFiled 2025-03-06
    FY 2025 · Full-year highlights

    Revenue ¥1.08B, +9,9% YoY; Operating income −8,4% YoY.

    Revenue¥1.08B+9,9 % YoY
    Operating income¥223.4M−8,4 % YoY
    Net income¥192.7M+9,2 % YoY
    Free cash flow-¥431.2M−126,3 % YoY
    EPS
    Operating cash flow¥114.3M+20,6 % YoY
    Financials
    Income statement
    Revenue¥1.08B
    Gross profit¥809.5M
    Operating income¥223.4M
    Net income¥192.7M
    Margins
    Gross margin75.0%
    Operating margin20.7%
    Net margin17.9%
    FCF margin-40.0%
    Balance sheet
    Total assets¥3.97B
    Total liabilities¥2.61B
    Total equity¥1.36B
    Cash & equivalents¥121.7k
    Long-term debt¥1.70B
    Cash flow
    Operating cash flow¥114.3M
    CapEx-¥586.8M
    Free cash flow-¥431.2M
    SBC
    P&L flow · revenue → net income
    Revenue ¥1.29BOperating costs ¥1.09BFinance ¥40.2MNet income ¥197.0M
    Highlights
    • Revenue ¥1.08B, +9,9% YoY
    • Operating income −8,4% YoY
    • Net income +9,2% YoY
    • Free cash flow −126,3% YoY
    • Net margin 17.9%

    Valuation FY

    Market price
    ¥36,00
    Market cap
    ¥14.90B
    Enterprise value
    ¥16.80B
    P/E
    75.6x
    Non-GAAP P/E
    EV / Revenue
    13.0x
    EV / Op income
    84.4x
    EV / OCF
    147.0x
    P / B
    9.3x
    P / Tangible book
    9.3x
    Tangible book
    ¥1.60B
    Net cash
    -¥1.90B
    Current ratio
    1.1
    Debt / equity
    1.2
    ROA
    4.3%
    ROE
    12.4%
    Cash conversion
    57.0%
    CapEx / revenue
    -52.2%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Active Pharmaceutical Ingredients (API)
    low · llm_fanout_v2
    Branded / Innovative Medicines
    low · llm_fanout_v2

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin20,8 %Above P75
    Net Margin17,8 %Best in class
    ROE12,4 %Above median
    Capex / Rev-52,2 %Bottom quartile
    D/E1,18Bottom quartile
    Cash Conv0,57Below median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    • Reference data
    How metrics are computed
    • Ev To Revenue
      enterprise_value / revenue
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Price To Earnings
      market_price / (net_income / shares_outstanding_diluted)
    • Return On Assets
      net_income / total_assets
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    Source documents
    • Wedge Industrial Co Ltd Market data — financials · 2026-07-09

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    000534.SZCanonical
    Shenzhen Stock Exchange · CNY

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2025-03-06 17:32 UTCEARNINGSAnnual results — FY 2025 Revenue CNY 1.08B · Net CNY 192.7M
    2024-03-29 17:08 UTCEARNINGSAnnual results — FY 2024 Revenue CNY 981.4M · Net CNY 176.6M
    2023-02-16 15:13 UTCEARNINGSAnnual results — FY 2023 Revenue CNY 793.8M · Net CNY 101.7M
    2022-03-27 13:01 UTCEARNINGSAnnual results — FY 2022 Revenue CNY 656.3M · Net CNY 95.3M
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data · Reference data Premium coverage